Entera Bio Stock Total Debt

ENTXWDelisted Stock  USD 0  0.00  0.00%   
Entera Bio fundamentals help investors to digest information that contributes to Entera Bio's financial success or failures. It also enables traders to predict the movement of Entera Stock. The fundamental analysis module provides a way to measure Entera Bio's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Entera Bio stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Entera Bio Company Total Debt Analysis

Entera Bio's Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.

Total Debt

 = 

Bonds

+

Notes

More About Total Debt | All Equity Analysis

Current Entera Bio Total Debt

    
  91 K  
Most of Entera Bio's fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Entera Bio is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Competition

Based on the latest financial disclosure, Entera Bio has a Total Debt of 91 K. This is much higher than that of the Oil, Gas & Consumable Fuels sector and significantly higher than that of the Energy industry. The total debt for all United States stocks is notably lower than that of the firm.

Entera Total Debt Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Entera Bio's direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Entera Bio could also be used in its relative valuation, which is a method of valuing Entera Bio by comparing valuation metrics of similar companies.
Entera Bio is currently under evaluation in total debt category among its peers.

Entera Fundamentals

About Entera Bio Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Entera Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Entera Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Entera Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.
You can also try the CEOs Directory module to screen CEOs from public companies around the world.

Other Consideration for investing in Entera Stock

If you are still planning to invest in Entera Bio check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Entera Bio's history and understand the potential risks before investing.
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Global Correlations
Find global opportunities by holding instruments from different markets